Connect Biopharma Holdings Limited (CNTB)

1,3700 +0,0500 (+3,79%) Börsenschluss: 04:00PM EDT

Connect Biopharma Holdings Limited

12265 El Camino Real
Suite 350
San Diego, CA 92130
United States
858 727 1040
https://www.connectbiopharm.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 81

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Wubin Pan M.B.A., Ph.D.	Co-Founder, President & Chairman of the Board of Directors	N/A	N/A	1965
Dr. Zheng Wei Ph.D.	Co-Founder, CEO & Director	N/A	N/A	1964
Mr. Steven Chan	Chief Financial Officer	N/A	N/A	1972
Mr. Jiang Bian J.D.	General Counsel & Chief Compliance Officer	N/A	N/A	N/A
Dr. Lei Sun Ph.D.	VP of Biologics & Head of CMC	N/A	N/A	1964
Dr. Raul Collazo Ph.D.	VP & Global Head of Medical Affairs	N/A	N/A	N/A
Dr. Malinda V. Longphre Ph.D.	VP & Head of US Clinical Operations	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Corporate Governance

Connect Biopharma Holdings Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.